DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,452.222 B2 Kraynov Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,452.222 B2 Kraynov Et Al USOO9452222B2 (12) United States Patent (10) Patent No.: US 9,452.222 B2 Kraynov et al. (45) Date of Patent: Sep. 27, 2016 (54) NUCLEIC ACIDS ENCODING MODIFIED 4,680,338 A 7, 1987 Sundoro RELAXN POLYPEPTIDES 4,689,406 A 8, 1987 Banks et al. 4,699,784. A 10, 1987 Shih et al. 4,738,921 A 4, 1988 Belagaje et al. (71) Applicant: Ambrx, Inc., La Jolla, CA (US) 4,755.465 A 7/1988 Gray et al. 4,837,148 A 6/1989 Cregg (72) Inventors: Vadim Kraynov, San Diego, CA (US); 4,859,600 A 8/1989 Gray et al. Nick Knudsen, San Diego, CA (US); 4,876, 197 A 10, 1989 Burke et al. 4,880,734 A 11/1989 Burke et al. Ahma Hewet, Chula Vista, CA (US); 4.902,502 A 2f1990 Nitecki et al. Kristine De Dios, San Diego, CA (US); 4,904,584 A 2, 1990 Shaw Jason Pinkstaff, Encinitas, CA (US); 4,929,555 A 5/1990 Cregg et al. Lorraine Sullivan, San Diego, CA 5,021,234 A 6, 1991 Ehrenfeld (US) 5,089,398 A 2/1992 Rosenberg et al. 5,122,614 A 6/1992 Zalipsky 5,145,962 A 9, 1992 Hudson et al. (73) Assignee: AMBRX, INC., La Jolla, CA (US) 5,162,601 A 11/1992 Slightom 5,219,564 A 6/1993 Zalipsky et al. (*) Notice: Subject to any disclaimer, the term of this 5,229,490 A 7, 1993 Tam patent is extended or adjusted under 35 5,231,178 A 7, 1993 Holtz et al. U.S.C. 154(b) by 0 days. 5,252,714 A 10, 1993 Harris et al. 5,281,698 A 1/1994 Nitecki 5,290,686 A 3, 1994 Kendal et al. (21) Appl. No.: 14/152,302 5,324,639 A 6/1994 Brierley et al. 5,324,844 A 6/1994 Zalipsky (22) Filed: Jan. 10, 2014 5,382,657 A 1/1995 Karasiewicz et al. 5,446,090 A 8, 1995 Harris (65) Prior Publication Data 5,468.478 A 11/1995 Saifer et al. 5,473,034 A 12/1995 Yasui et al. US 2014/O194357 A1 Jul. 10, 2014 5,476,653 A 12, 1995 Pitt et al. 5,516,657 A 5/1996 Murphy et al. 5,516,673 A 5/1996 Margel et al. Related U.S. Application Data 5,532,142 A 7/1996 Johnston et al. 5,559,213 A 9, 1996 Hakimi et al. (62) Division of application No. 13/212,101, filed on Aug. 5,571,709 A 11/1996 Devauchelle et al. 17, 2011, now Pat. No. 8,735,539. 5,580,723 A 12/1996 Wells et al. (60) Provisional application No. 61/374,582, filed on Aug. (Continued) 17, 2010. FOREIGN PATENT DOCUMENTS (51) Int. Cl. CA 2707840 2, 2009 CI2N 5/10 (2006.01) DE 3218121 A1 11F1983 CI2N 15/16 (2006.01) EP O36 676 A1 9, 1981 CI2N 15/63 (2006.01) EP O36 776 A2 9, 1981 C07K I4/64 (2006.01) EP O52 322 A2 5, 1982 EP O58 481 A1 8, 1982 A6 IK 47/48 (2006.01) EP O73 657 A1 3, 1983 A61 K 38/00 (2006.01) EP 102 324 A2 3, 1984 (52) U.S. Cl. EP 121 775 A1 10, 1984 CPC ......... A61K 47/48215 (2013.01); C07K 14/64 EP 127839 A2 12, 1984 (2013.01); A61 K 38/00 (2013.01) (Continued) (58) Field of Classification Search None OTHER PUBLICATIONS See application file for complete search history. Adams et al., “Molecular cloning of mouse immunoglobulin heavy (56) References Cited chain messenger ribonucleic acids coding for mu, alpha, gamma 1. gamma 2a, and gamma 3 chains’. Biochemistry (1980) U.S. PATENT DOCUMENTS 19(12):2711-2719. (Continued) 3,773.919 A 11/1973 Boswell et al. 4,289,872 A 9, 1981 Denkewalter et al. 4.412,989 A 11, 1983 Iwashita et al. 4.414,148 A 11, 1983 Jansen et al. Primary Examiner — Christine J Saoud 4.485,045 A 11/1984 Regen (74) Attorney, Agent, or Firm — LeClairRyan, a 4,511,502 A 4, 1985 Builder et al. professional corporation; Robin L. Teskin 4,511,503 A 4, 1985 Olson et al. 4,512.922 A 4, 1985 Jones et al. 4,544.545 A 10/1985 Ryan et al. (57) ABSTRACT 4,551,433 A 11, 1985 DeBoer 4,569,789 A 2f1986 Blattler et al. Modified relaxin polypeptides and their uses thereof are 4,619,794. A 10, 1986 Hauser provided. 4,659,839 A 4, 1987 Nicolotti et al. 4,670,417 A 6, 1987 Iwasaki et al. 4,671,958 A 6, 1987 Rodwell et al. 19 Claims, 26 Drawing Sheets US 9,452.222 B2 Page 2 (56) References Cited 6,610,281 B2 8, 2003 Harris 6,646,110 B2 11/2003 Nissen et al. U.S. PATENT DOCUMENTS 6,927,042 B2 8/2005 Schultz et al. 7,045,337 B2 5/2006 Schultz et al. 5,583,023 A 12/1996 Cerutti et al. 7,083,970 B2 8, 2006 Schultz et al. 5,602,034 A 2/1997 Tekamp-Olson 7,230,068 B2 6/2007 Wilson 5,605,827. A 2, 1997 Jackwood et al. 7,332,571 B2 22008 Miao 5,612.460 A 3/1997 Zalipsky 7,385,028 B2 6/2008 Miao 5,629,203 A 5, 1997 Shuster 7,632,823 B2 12/2009 Tian 5,629,384. A 5/1997 Veronese et al. 7,632,924 B2 12/2009 Cho 5,643,575 A 7, 1997 Martinez et al. 7,638.299 B2 12/2009 Cho 5,650,234 A 7, 1997 Dolence et al. 7,638,491 B2 12/2009 Miao 5,672,662 A 9/1997 Harris et al. 7,696.312 B2 4/2010 Miao 5,674,706 A 10/1997 Shuster 7,736,872 B2 6/2010 Paulsel RE35,749 E 3/1998 Rosenberg et al. 7,737,226 B2 6/2010 Wilson 5,736,625 A 4, 1998 Callstrom et al. 7.816,320 B2 10/2010 Hays 5.739.208 A 4, 1998 Harris 7,820,766 B2 10/2010 Wilson 5,747,646 A 5/1998 Hakimi et al. 7,829,310 B2 11/2010 Paulsel 5,750,373 A 5, 1998 Garrard et al. 7,838,265 B2 11/2010 Paulsel 5.753220 A 5, 1998 Suzuki et al. 7,846,689 B2 12/2010 Paulsel 5,762935 A 6, 1998 Smith et al. 7,858,344 B2 12/2010 Paulsel 5,766,885 A 6/1998 Carrington et al. 7,883,866 B2 2/2011 Paulsel 5,808,096 A 9/1998 Zalipsky 7,888,533 B2 2/2011 Tian 5,824,778 A 10/1998 Ishikawa et al. 7.919,591 B2 4, 2011 Sheffer 5,824,784. A 10/1998 Kinstler et al. 7,928,163 B2 4/2011 Miao 5,834,250 A 11/1998 Wells et al. 7,939,496 B2 5/2011 Cho 5,834,594. A 1 1/1998 Hakimi et al. 7,947,473 B2 5/2011 Buechler 5,843,733. A 12/1998 Estes 7.959,926 B2 6, 2011 Buechler 5,849,860 A 12/1998 Hakimi et al. 8,008,428 B2 8/2011 Wilson 5,858,368 A 1/1999 Smith et al. 8,008,456 B2 8, 2011 Miao 5,861,279 A 1/1999 Zhang et al. 8,012.931 B2 9/2011 Cujec 5,871,986 A 2/1999 Boyce 8,022, 186 B2 9, 2011 Sheffer 5,891,676 A 4/1999 Estes 8,048,988 B2 11/2011 Miao 5,900.461 A 5, 1999 Harris 8,053,560 B2 11/2011 Sheffer 5,911,997 A 6, 1999 Schwabe et al. 8,071,809 B2 12/2011 Tian 5,932,462 A 8, 1999 Harris et al. 8,080,391 B2 12/2011 Buechler 5,939,285 A 8, 1999 Devauchelle et al. 8,093,356 B2 1/2012 Hays 5,965,393 A 10/1999 Hasnain et al. 8,097,702 B2 1/2012 Cho 5,980,948 A 1 1/1999 Goedemoed et al. 8,114,630 B2 2/2012 Kraynov 5,989,868 A 1 1/1999 Harrison et al. 8,119,603 B2 2/2012 Cho 5.990.237 A 1 1/1999 Bentley et al. 8, 143,216 B2 3/2012 Cho 6,004,573 A 12/1999 Rathi et al. 8,153,758 B2 4/2012 Miao 6,013,433 A 1/2000 Pellett et al. 8,163,695 B2 4/2012 Hays 6,013,478 A 1/2000 Wells et al. 8, 178,108 B2 5, 2012 Buechler 6,017,731 A 1/2000 Tekamp-Olson et al. 8, 178.494 B2 5/2012 Hays 6,083,723 A 7/2000 Tekamp-Olson 8,232,371 B2 7/2012 Cho 6,096,304 A 8, 2000 McCutchen 8,263,740 B2 9.2012 Miao 6,126,944. A 10/2000 Pellett et al. 8,278.418 B2 10/2012 Tian 6,129,912. A 10/2000 Hortin et al. 8,329,869 B2 12/2012 Kraynov 6,168,932 B1 1/2001 Uckun et al. 8,367,612 B2 2/2013 Miao 6,183,985 B1 2/2001 Shuster 8,383,365 B2 2/2013 Cujec 6,183,987 B1 2/2001 Van De Wiel et al. 8,399.614 B2 3/2013 Miao 6,201,072 B 1 3/2001 Rathi et al.
Load more

Recommended publications
  • Generate Metabolic Map Poster
    Authors: Pallavi Subhraveti Ron Caspi Peter Midford Peter D Karp An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Ingrid Keseler Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_003855395Cyc: Shewanella livingstonensis LMG 19866 Cellular Overview Connections between pathways are omitted for legibility.
    [Show full text]
  • Antiviral Compounds Antivirale Verbindungen Composes Antiviraux
    (19) TZZ_Z _T (11) EP 1 778 702 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07F 9/141 (2006.01) C07D 207/08 (2006.01) 13.07.2011 Bulletin 2011/28 A61K 31/662 (2006.01) A61P 31/12 (2006.01) (21) Application number: 05791144.8 (86) International application number: PCT/US2005/025503 (22) Date of filing: 18.07.2005 (87) International publication number: WO 2006/020276 (23.02.2006 Gazette 2006/08) (54) ANTIVIRAL COMPOUNDS ANTIVIRALE VERBINDUNGEN COMPOSES ANTIVIRAUX (84) Designated Contracting States: (74) Representative: Reitstötter - Kinzebach AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Patentanwälte HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI Sternwartstrasse 4 SK TR 81679 München (DE) Designated Extension States: AL BA HR MK YU (56) References cited: EP-A- 1 337 550 WO-A-00/09543 (30) Priority: 16.07.2004 US 588633 P WO-A-00/59929 WO-A-98/17679 27.07.2004 US 591635 P WO-A-99/07733 WO-A-02/060926 WO-A-03/053349 WO-A-03/064416 (43) Date of publication of application: WO-A-03/064455 WO-A-03/064456 02.05.2007 Bulletin 2007/18 WO-A-03/066103 WO-A-03/099274 WO-A-03/099316 US-A1- 2003 186 895 (60) Divisional application: US-A1- 2003 224 977 US-A1- 2004 048 802 10178084.9 / 2 316 839 US-B1- 6 608 027 (73) Proprietor: GILEAD SCIENCES, INC.
    [Show full text]
  • Purification and Characterization of the Higher Plant Enzyme L-Canaline Reductase (L-Canavanine Catabolism/Plant Nitrogen Metabolism/Leguminosae) GERALD A
    Proc. Natd. Acad. Sci. USA Vol. 89, pp. 1780-1784, March 1992 Biochemistry Purification and characterization of the higher plant enzyme L-canaline reductase (L-canavanine catabolism/plant nitrogen metabolism/Leguminosae) GERALD A. ROSENTHAL T. H. Morgan School of Biological Sciences, University of Kentucky, Lexington, KY 40506 Communicated by John S. Boyer, December 3, 1991 (receivedfor review April 20, 1991) ABSTRACT A newly discovered enzyme, L-canaline re- oglutaric acid to generate stoichiometrically a canaline-2- ductase (NADPH:L-canaline oxidoreductase, EC 1.6.6.-), has oxoglutaric acid oxime (5). Canaline also reacts readily with been isolated and purified from 10-day-old leaves of the jack the pyridoxal phosphate moiety of vitamin B6-containing bean Canavalia ensiformis (Leguminosae). This higher plant is enzymes to form a stable, covalently linked complex (6, 7). representative of a large number of legumes that synthesize In vitro analysis of canaline interaction with homogeneous L-canavanine, an important nitrogen-storing nonprotein amino ornithine aminotransferase (ornithine-oxo-acid aminotrans- acid. Canavanine-storing legumes contain arginase, which ferase; L-ornithine:2-oxo-acid aminotransferase, EC hydrolyzes L-canavanine to form the toxic metabolite L-cana- 2.6.1.13) reveals its marked ability to form an oxime complex line. Canaline reductase, having a mass of =167 kDa and with and thereby inhibit this pyridoxal phosphate-dependent composed of 82-kDa dimers, catalyzes a NADPH-dependent enzyme (8). As little as 10 nM canaline causes a significant reductive cleavage of L-canaline to L-homoserine and ammo- reduction in ornithine aminotransferase activity (9). nia. This is the only enzyme known to use reduced NADP to Canavanine-storing legumes can accumulate high levels of cleave an O-N bond.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,776,844 B2 Yu Et Al
    USOO777684.4B2 (12) United States Patent (10) Patent No.: US 7,776,844 B2 Yu et al. (45) Date of Patent: Aug. 17, 2010 (54) N-(PHOSPHONOALKYL)-AMINO ACIDS, 7,429,575 B2 9/2008 Yu et al. DERVATIVES THEREOF AND 2005, 016491.6 A1 7/2005 Leadbetter et al. COMPOSITIONS AND METHODS OF USE OTHER PUBLICATIONS (76) Inventors: Ruey J. Yu, 655 Stump Rd., Chalfont, Struninet al., 1989, CAS. 111:233525.* PA (US)18914; Eugene J. Van Scott, 3 Shi et al., 2004, CAS;142. 231739.* Hidden La., Abington, PA (US) 19001 Li et al., 2005, CAS; 143: 158351.* Sandeman et al., 2002, CAS: 137:274431.* (*) Notice: Subject to any disclaimer, the term of this Single co's i. 164: patent is extended or adjusted under 35 Stahl e et et al., al., 1995, CAS:si. 124:563.10.* U.S.C. 154(b) by 0 days. Jezowska-Bojczuk et al., 1994, CAS: 120:28.1638.* Strumin et al., 1989, CAS: 111:194894.* (21) Appl. No.: 12/428,906 Balthazor et al., 1987, CAS: 106:50457.* The Merck Index. "An Encyclopedia of Chemicals, Drugs, and (22) Filed: Apr. 23, 2009 Biologicals.” (2001) p. 1768, (2 pgs.), 13th Edition, O'Neil et al. (Ed.), Merck & Co., Inc., Whitehouse Station, N.J. (65) Prior Publication Data Wester et al., 1991, CAS: 114:242443. US 2009/0208499 A1 Aug. 20, 2009 * cited by examiner Related U.S. Application Data Primary Examiner Rei-tsang Shiao - - - (74) Attorney, Agent, or Firm Panitch Schwarze Belisario & (62) Division of application No. 12/194203, filed on Aug.
    [Show full text]
  • | Mo Naman Attituunika Mitatti
    |MO NAMAN ATTITUUNIKAUS009962450B2 MITATTI (12 ) United States Patent (10 ) Patent No. : US 9 , 962 , 450 B2 Kraynov et al. ( 45) Date of Patent : May 8 , 2018 ( 54 ) METHOD OF TREATING HEART FAILURE 4 ,659 ,839 A 4 / 1987 Nicolotti et al . WITH MODIFIED RELAXIN POLYPEPTIDES 4 ,670 ,417 A 6 / 1987 Iwasaki et al. 4 ,671 , 958 A 6 / 1987 Rodwell et al. 4 ,680 , 338 A 7 / 1987 Sundoro ( 71) Applicant : AMBRX , INC . , La Jolla , CA (US ) 4 ,689 ,406 A 8 / 1987 Banks et al . 4 ,699 ,784 A 10 / 1987 Shih et al . ( 72 ) Inventors : Vadim Kraynov , San Diego , CA (US ) ; 4 ,738 , 921 A 4 / 1988 Belagaje et al. Nick Knudsen , San Diego , CA (US ) ; 4 ,755 ,465 A 7 / 1988 Gray et al. 4 ,837 , 148 A 6 / 1989 Cregg Amha Hewet, Chula Vista , CA (US ) ; 4 ,859 ,600 A 8 / 1989 Gray et al . Kristine De Dios, San Diego , CA (US ) ; 4 , 876 , 197 A 10 / 1989 Burke et al. Jason Pinkstaff , Encinitas, CA (US ) ; 4 , 880 ,734 A 11/ 1989 Burke et al . Lorraine Sullivan , San Diego , CA 4 , 902 ,502 A 2 / 1990 Nitecki et al . 4 , 904 , 584 A 2 / 1990 Shaw ( US ) 4 ,929 , 555 A 5 / 1990 Cregg et al. 5 ,021 , 234 A 6 / 1991 Ehrenfeld (73 ) Assignee : AMBRX , INC. , La Jolla , CA (US ) 5 ,089 ,398 A 2 / 1992 Rosenberg et al . 5 , 122 ,614 A 6 / 1992 Zalipsky ( * ) Notice : Subject to any disclaimer , the term of this 5 , 145 , 962 A 9 / 1992 Hudson et al.
    [Show full text]
  • Zone Finhibton Inmillimeters
    US006191168B1 (12) United States Patent (10) Patent N0.: US 6,191,168 B1 Rubenstein (45) Date of Patent: Feb. 20, 2001 (54) METHODS FOR THE USE OF NONPROTEIN CA 126: 268319, Breton et al, 1997.* AMINO ACIDS AS THERAPEUTIC AGENTS Bell. (1958). “Canavanine and Related Compounds in Legu minosae,” Biochem J. 70:617—619. (75) Inventor: Edward Rubenstein, 5 Waverly Pl., Bisby et al. (1994). Phytochemical Dictionary of the Legu Hillsborough, CA (US) 94010 minose, vol. 1—2. (Title page and table of contents only). Butler et al. (1967). “Uptake and Metabolism of Inorganic (73) Assignee: Edward Rubenstein, Hillsborough, CA Forms of Selenium—75 by Spiroa'ela Oligorrhiza, ” Aust. J. (Us) Biol. Sci. 20:77—86. Conn. (1981). “Secondary Plant Products” The Biochemistry (*) Notice: Under 35 U.S.C. 154(b), the term of this of Plants vol. 7(Title page and table of contents only). patent shall be extended for 0 days. CoWie et al. (1957). “Biosynthesis by Escherichia Coli of Active Altered Proteins Containing Selenium Instead of (21) Appl. No.: 09/324,181 Sulfur,” Biochem et Biophysica Acta. 26:252—261. Gennaro ed. (1995). Remington." The Science and Practice Filed: Jun. 1, 1999 (22) The Science and of Pharmacy (Title page and table of Related US. Application Data contents only). (60) Provisional application No. 60/087,746, ?led on Jun. 2, (List continued on neXt page.) 1998. Primary Examiner—Rebecca Cook (51) Int. Cl.7 ................................................. .. A61K 31/195 (74) Attorney, Agent, or Firm—Morrison & Foerster LLP (52) US. Cl. ........................ .. 514/561; 514/210; 514/274; 514/419; 514/423; 514/315; 514/354; 514/538; (57) ABSTRACT 514/562; 514/563; 514/564; 514/565 Provided are compositions comprising nonprotein amino (58) Field of Search ..................................
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION L-Canaline Item No. 9002357 CAS Registry No.: 496-93-5 Formal Name: O-amino-L-homoserine O MF: C H N O 4 10 2 3 O FW: 134.1 HO NH2 Purity: ≥95% NH Stability: ≥2 years at -20°C 2 Supplied as: A crystalline solid Laboratory Procedures For long term storage, we suggest that L-canaline be stored as supplied at -20°C. It should be stable for at least two years. L-Canaline is supplied as a crystalline solid. A stock solution may be made by dissolving the L-canaline in the solvent of choice. L-Canaline is soluble in organic solvents such as DMSO which should be purged with an inert gas. The solubility of L-canaline in this solvent is approximately 1 mg/ml. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of L-canaline can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of L-canaline in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description L-Canaline is an aminooxy analog of ornithine that irreversibly inhibits aminotransferases (transaminases), 1-3 including ornithine aminotransferase (Ki = 2 µM). It forms oximes with α-keto acids and aldehydes, most notably with pyridoxal phosphate, an essential cofactor of aminotransferases.3 L-Canaline is naturally found in plants, including legumes, and is involved in the metabolism of L-canavanine, an aminooxy analog of arginine.4 It is cytotoxic to a range of organisms, including bacteria, insects, and parasites.2,4,5 References 1.
    [Show full text]
  • United States Patent Office Patented Nov
    3,704,246 United States Patent Office Patented Nov. 28, 1972 2 (I) R 3,704,246 AMNO ACD DERVATIVES ( CH).--N Miklos Bodanszky, Shaker Heights, Ohio, assignor to R2-C YoH-R E. R. Squibb & Sons, Inc., New York, N.Y. No Drawing. Continuation-in-part of application Ser. No. R-i-o-c6 798,790, Feb. 12, 1969, which is a continuation-in-part wherein R is the residue of an a-amino acid, R1 is hydro of abandoned application Ser. No. 451,609, Apr. 28, gen, lower alkyl, hydroxy-substituted lower alkyl, or 1965. This application Dec. 16, 1970, Ser. No. 98,924 lower alkyl lower alkoxy; R and R3 each is hydrogen, int. C. C07d 87/54 lower alkyl, hydroxy-substituted lower alkyl, lower alkyl U.S. C. 260-333 9 Claims 10 lower alkoxy, or R and R3 together with the carbons to which they are joined form a phenyl ring which may be unsubstituted or substituted by halogen or nitro, and m ABSTRACT OF THE DESCLOSURE is an integer from 0 to 3. New lactone intermediates useful in the synthesis of 5 DETAILED DESCRIPTION OF THE INVENTION peptides are prepared by reacting an a-amino acid with Any a-amino acid may be treated according to this an active carbonyl compound which forms a Schiff's base. invention. This includes the naturally occurring ox-amino The latter is treated with a condensing agent so that acids see for example, Hackh's Chemical Dictionary, cyclization occurs and a lactone is formed from which a 3rd ed.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0161543 A1 Yu Et Al
    US 2007 O161543A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0161543 A1 Yu et al. (43) Pub. Date: Jul. 12, 2007 (54) N-(PHOSPHONOALKYL)-AMINO ACIDS, (52) U.S. Cl. .............................. 514/7: 514/114: 530/331; DERVATIVES THEREOF AND 558/170 COMPOSITIONS AND METHODS OF USE (76) Inventors: Ruey J. Yu, Chalfont, PA (US); Eugene J. Van Scott, Abington, PA (US) (57) ABSTRACT Correspondence Address: AKN GUMPSTRAUSS HAUER & FELD The present invention relates to an N-(phosphonoalkyl)- 6. COMMERCE SQUARE amino acid, a related compound or a derivative thereof, the 2005 MARKET STREET, SUITE 2200 N-(phosphonoalkyl)-amino acid, related compound or PHILADELPHIA, PA 19103 (US) derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in Stereoisomeric or non (21) Appl. No.: 11/621,287 Stereoisomeric form, other than N-(phosphonomethyl)-gly (22) Filed: Jan. 9, 2007 cine or N.N-bis(phosphonomethyl)-glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, Related U.S. Application Data a related compound or a derivative thereof in a form as a free (60) Provisional application No. 60/757,614, filed on Jan. acid, salt, partial salt, lactone, amide or ester, or in Stereoi 10, 2006. sy u. Is Someric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic Publication Classification administration to a mammalian Subject, as well as a method of administering an effective amount of Such a composition (51) Int. Cl. A6 IK 38/05 (2006.01) for alleviating or improving a condition, disorder, symptom A6 IK 3/66 (2006.01) or syndrome associated with at least one of a nervous, C07K 5/10 (2006.01) vascular, musculoskeletal or cutaneous system.
    [Show full text]
  • Generated by SRI International Pathway Tools Version 25.0, Authors S
    Authors: Pallavi Subhraveti Ingrid Keseler Quang Ong Ron Caspi An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Tim Holland Peter D Karp Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Saur904776Cyc: Staphylococcus aureus aureus IS-24 Cellular Overview Connections between pathways are omitted for legibility. Anamika Kothari guaninehypoxanthine indole- pro 3-acetate (S)-lactate (S)-lactate uracil H + H + H + H + H + H + H + H + H + ammonium IS24_0964 IS24_2784 AtpC AtpF AtpI AtpA AtpD AtpE AtpB AtpH AtpG Amt PbuG PutP PyrP IS24_1600 + + + + + + + + + indole- H H H H H H H H H uracil (S)-lactate (S)-lactate ammonium 3-acetate guanine pro hypoxanthine Cofactor, Prosthetic Group, Electron Carrier, and Vitamin Biosynthesis Chemoautotrophic Amino Acid Degradation Energy Metabolism Detoxification UDP-N-acetyl- an [apo BCAA an apo-[methylmalonyl- campest- a (3R)-3- 3-(4- valine degradation I a [formate C testosterone a phosphate cob(II)yrinate a,c- glutamine SAM a reduced flavodoxin α-D-muramoyl- di-trans,octa-cis 4-methyl-2- dehydrogenase CoA:pyruvate biotin 5-hydroxytryptophol β hydroxyhexanoyl- hydroxyphenyl) flavin biosynthesis I (bacteria and plants) L-ascorbate biosynthesis V L-ascorbate
    [Show full text]
  • Pka Data Compiled by R
    pKa Data Compiled by R. Williams page-1 pKa Values INDEX Inorganic 2 Phenazine 24 Phosphates 3 Pyridine 25 Carboxylic acids 4, 8 Pyrazine 26 Aliphatic 4, 8 Aromatic 7, 8 Quinoline 27 Phenols 9 Quinazoline 27 Alcohols and oxygen acids 10, 11 Quinoxaline 27 Amino Acids 12 Special Nitrogen Compounds 28 Peptides 13 Hydroxylamines 28 Nitrogen Compounds 14 Hydrazines 28 Aliphatic amines 15, 17, 19 Semicarbazones 28 Cyanoamines 16 Amidoximes 28 Anilines 17, 18, 20 Thiols 29 Nucleosides 21 Carbon Acids 30,31 Special Table Heterocycles 22 Indicators 31 Acridine 23 References 32-34 Benzoquinoline 24 Cinnoline 23 Hydantoin 24 Imidazole 24 For complex chelating agents, see also reference 77. Note. This document was compiled by W.P. Jencks and has been added to by F.H. Westheimer pKa Data Compiled by R. Williams page-2 ACIDS Compound pK Ref. H3PO2 2.0, 2.23* 28 H2PO4– 7.21* 77 AgOH 3.96 4 HPO4_ 12.32* 77 Al(OH)3 11.2 28 H3PO3 2.0 28 As(OH)3 9.22 28 H PO – 6.58* 77 H3AsO4 2.22, 7.0, 13.0 28 2 3 H4P2O7 1.52* 77 H2AsO4– 6.98* 77 H P O – 2.36* 77 HAsO4* 11.53* 77 3 2 7 = As2O3 0 4 H2P2O7 6.60* 77 H3AsO3 9.22* HP2O7= 9.25* 77 H3BO3 9.23* 28 HReO4 -1.25 30 H2B4O7 4.00 34 HSCN 4.00 34 HB4O7 9.00 34 H2SeO3 2.6, 8.3, 2.62* 28 Be(OH)2 3.7 4 HSeO3 8.32 77 HBr -9.00 31 H2SeO4 Strong, 2.0 28 HOBr 8.7 28 HSeO4 2.00 34 HOCl 7.53, 7.46 28, 33 H3SiO3 10.0 34 HClO2 2.0 28 H2SO3 1.9, 7.0, 1.76* 28, 77 HClO3 -1.00 28 H2SO4 -3.0, 1.9 28 HClO4 (70%) -10.00 31 HSO3 7.21* 77 CH SO H -0.6 31 3 3 HSO4– 1.99* 77 HCN 9.40 34 H2S2O4 1.9 29 H CO 6.37, 6.35*, 3.58 34, 32 2 3 H2Se
    [Show full text]
  • Thermochemistry of Amino Acids and Constrained Diamines
    W&M ScholarWorks Dissertations, Theses, and Masters Projects Theses, Dissertations, & Master Projects 2012 Thermochemistry of Amino Acids and Constrained Diamines Erica Jane Tullo College of William & Mary - Arts & Sciences Follow this and additional works at: https://scholarworks.wm.edu/etd Part of the Analytical Chemistry Commons, Biochemistry Commons, and the Physical Chemistry Commons Recommended Citation Tullo, Erica Jane, "Thermochemistry of Amino Acids and Constrained Diamines" (2012). Dissertations, Theses, and Masters Projects. Paper 1539623596. https://dx.doi.org/doi:10.21220/s2-vp4j-1g27 This Dissertation is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Dissertations, Theses, and Masters Projects by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. Thermochemistry of Amino Acids and Constrained Diamines Erica Jane Tullo Oxford, Pennsylvania Master of Science, The College of William and Mary, 2006 Bachelor of Science, Washington College, 2000 A Dissertation presented to the Graduate Faculty of the College of William and Mary in Candidacy for the Degree of Doctor of Philosophy Department of Applied Science The College of William and Mary January, 2012 APPROVAL PAGE This Dissertation is submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Committee Chair Marga t Hamilton Professor John C. Poutsma, Chemistry The College of William and Mary Professor Mark K. Hinders, C~r. Applied Science The College of William and Mary 2JtlUJJ Z1C- Assistant Professor Hannes C. Schniepp, Applied Science The College of William and Mary a~ ~L/b/ Professor David E."k:ranbuehl, cfiemistry The College of William and Mary ABSTRACT PAGE The gas-phase proton affinities of several highly basic amino acids and diamines were determined using the extended kinetic method in an ESI-quadrupole ion trap instrument.
    [Show full text]